GnRH AGONISTS FOR GENDER DYSPHORIA
GnRH agonists are a class of medicines that pause puberty, and they work by lowering the hormone signals that drive it. After a brief initial rise, they switch off the pituitary’s release of the hormones that tell the ovaries or testes to make estrogen or testosterone, which pauses pubertal development for as long as the medication is taken.
They have been used for decades to treat unusually early (precocious) puberty, and their effect is reversible: when the medication stops, puberty resumes. In care for gender dysphoria, they are used to pause unwanted puberty and give a young person time.
This page uses “puberty-pausing medications” for these medicines after the first mentions; you may also see them called GnRH analogues, puberty blockers, or puberty suppression, which describe the same class of treatment.
WHAT ARE GnRH AGONISTS, AND HOW DO THEY WORK?
GnRH agonists are lab-made versions of a natural hormone (gonadotropin-releasing hormone) that the body normally releases in pulses to start and drive puberty.
When given continuously as a medication rather than in pulses, they first cause a short surge in puberty hormones lasting about a week, and then the pituitary gland “downregulates” and stops responding, which lowers luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and, in turn, the estrogen or testosterone the gonads produce (StatPearls, 2025).
The result is a reversible pause in puberty for as long as the medication continues.
WHAT THE RESEARCH SHOWS
The mechanism is well understood because these medicines have been studied since the 1980s. Continuous dosing produces a brief “flare” of LH and FSH for roughly a week, followed over about two weeks by receptor desensitization that suppresses those hormones and the sex steroids they drive (standard-of-care overview, 2026). Because the suppression depends on ongoing dosing, stopping the medication allows the body’s own puberty to resume (Frontiers in Endocrinology, 2024).
Sources: FDA-approved options and dosing intervals for early puberty, Frontiers in Pediatrics (2022) and Medscape clinical reference (2024). The same medicines are used off the earliest labels in gender care.
WHAT THEY DO, AND WHAT THEY DON'T DO
Puberty-pausing medications pause the development of unwanted secondary sex characteristics, such as a deepening voice or breast growth, while it is taken. It does not create the features of another puberty and does not cause permanent physical changes on its own; that is why clinicians describe it as pressing pause rather than making a lasting change (Mayo Clinic). It also pauses egg and sperm maturation while taken, which is covered on our fertility page.
KNOWN AND MONITORED EFFECTS
The effects clinicians watch for are generally mild and manageable, and the medication is monitored throughout treatment:
-
A dip in bone density scores while on the medication, which long-term research found generally recovers once hormones begin (JAMA Pediatrics, 2023).
-
Mild “menopause-like” effects such as hot flashes, headaches, fatigue, or mood changes,
which are usually minor.
-
A temporary pause in fertility, which returns after stopping in the medication-only stage.
-
Rarely, the US Food and Drug Administration has noted cases of increased pressure around the brain (pseudotumor cerebri) with this drug class, so severe headaches or vision changes should be reported promptly (reported in Managed Healthcare Executive, 2026).
WHAT IS KNOWN, AND WHAT ISN'T
How the medication works and its short-term effects are well established from decades of use in early puberty. Less certain are long-term outcomes specific to gender care, and independent evidence reviews have rated the evidence for benefits as low-certainty. That is a statement about the strength of the studies rather than proof of harm, and we cover it in full on our page about the risks of gender-affirming hormones in adolescents.
CONTENT NOTE
This is information, not medical advice. Whether this medication is appropriate for a particular young person is a decision for that young person, their family, and their qualified healthcare providers, based on individual circumstances.